Pfizer in advanced talks to buy global blood therapeutics for about $5 billion

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Listen to this article |
Pfizer Inc. is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline.